All In Biotech

Drug Trial Radar · NCT04086264

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

218

Actual

Start

Nov 6, 2019

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • AzacitidineDrug

    Commercially available formulation given subcutaneously (SC) or intravenous (IV)

  • IMGN632Drug

    Study formulation given intravenously (IV)

  • VenetoclaxDrug

    Commercially available formulation administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: approximately 3 years
  2. Preliminary antileukemia activityTime frame: approximately 20 months
  3. Minimal Residual Disease LevelsTime frame: approximately 18 months

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 269273

    Duarte, California

  • University Of California Irvine Medical Center /ID# 269275

    Orange, California

  • Moffitt Cancer Center /ID# 269269

    Tampa, Florida

  • Northwestern University- Robert H. Lurie Comprehensive Cancer Center /ID# 269642

    Chicago, Illinois

  • Dana-Farber Cancer Institute /ID# 269267

    Boston, Massachusetts

  • University of Michigan /ID# 269079

    Ann Arbor, Michigan

  • Mayo Clinic Hospital Rochester /ID# 269643

    Rochester, Minnesota

  • Roswell Park Cancer Institute /ID# 269266

    Buffalo, New York

  • New York Presbyterian Hospital Weill Cornell Medical Center /ID# 269271

    New York, New York

  • Duke University Health System /ID# 269268

    Durham, North Carolina

  • Cleveland Clinic - Cleveland /ID# 269272

    Cleveland, Ohio

  • MD Anderson Houston /ID# 269265

    Houston, Texas

  • Fred Hutchinson Cancer Research Center /ID# 269270

    Seattle, Washington

  • Centre Hospitalier de Versailles André Mignot /ID# 269287

    Le Chesnay, France

  • Institut Paoli-Calmettes /ID# 269080

    Marseille, Bouches-du-Rhone, France

  • IUCT Oncopole /ID# 269284

    Toulouse, Occitanie, France

  • Hôpital Saint-Louis /ID# 269282

    Paris, Paris, France

  • Centre Antoine-Lacassagne /ID# 269285

    Nice, Provence-Alpes-Côte d'Azur Region, France

  • Hospices Civils de Lyon - Centre Hospitalier Lyon-Sud /ID# 269286

    Pierre-Bénite, Rhone, France

  • Universitaetsklinikum Ulm /ID# 269686

    Ulm, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Muenster /ID# 269688

    Münster, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Leipzig /ID# 269682

    Leipzig, Saxony, Germany

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 269281

    Bologna, Bologna, Italy

  • Istituto Europeo Di Oncologia /ID# 269646

    Milan, Milano, Italy

  • Azienda Ospedaliero Universitaria Maggiore Della Carità /ID# 269280

    Novara, Novara, Italy

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 269279

    Meldola, Reggio Emilia, Italy

  • Hospital MD Anderson Cancer Center Madrid /ID# 269641

    Madrid, Madrid, Spain

  • Hospital Universitario y Politecnico La Fe /ID# 269278

    Valencia, Valencia, Spain

  • Oxford University Hospital NHS Trust /ID# 269647

    Oxford, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.